Pooled analyses from the large randomized trials EAGLE-2 and EAGLE-3 indicate that gepotidacin, a novel oral antibiotic, provides early and significant symptom relief for uncomplicated urinary tract infections (UTIs), comparable to the established treatment nitrofurantoin. This finding is particularly significant as it emphasizes patient-reported outcomes, such as symptom severity and impact on daily activities, which are often underrepresented in UTI trial endpoints despite their critical importance to patients' quality of life. Uncomplicated UTIs are a common bacterial infection that frequently causes pain, urgency, and disruption to daily routines. The analysis, which included over 3,100 participants aged 12 and older, assessed symptom severity using a standardized score covering frequency, urgency, dysuria, and suprapubic pain. Results showed that mean symptom scores, initially moderate to severe, were halved by days 2-4 of treatment in both the gepotidacin and nitrofurantoin groups. Furthermore, over 80% of participants experienced clinical improvement or complete symptom resolution during treatment. For those whose symptoms initially interfered with daily activities, more than half in each group reported no longer being affected within the first few days of treatment, with over 93% reporting minimal to no impact by the test-of-cure visit. The study suggests that new classes of antibiotics are needed to combat the growing issue of antibiotic resistance in UTIs, and gepotidacin shows promise in this regard.